BioPharma Resources

Drug Trial Radar · NCT05403541

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (gMG)

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 233 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

233

Actual

Start

Jun 27, 2022

Primary completion

Jan 10, 2025

Study completion Aug 7, 2026

Sponsor

Lead sponsor
Immunovant Sciences GmbHIndustry
Sponsor type
Industry
First posted
Jun 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this 4-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC) once a week (QW) or 340 mg SC QW or placebo. The primary efficacy endpoint will be assessed by change in the myasthenia gravis activities of daily living (MG- ADL) score in acetylcholine receptor antibody seropositive (AChRAb+) participants. In Period 2, participants previously treated with batoclimab will be re-randomized to stay on batoclimab (340 mg SC QW or 340 mg SC every two weeks) or receive placebo treatment. The secondary endpoint of maintenance of efficacy will be assessed by change in the MG- ADL score in AChRAb+ participants. Participants demonstrating a response to batoclimab during either Period 1 or 2 may enter the long-term extension (Period 3). Participants who complete Period 3 are eligible to participate in Period 4 (Optional Long-Term extension) according to their treatment assignment in Period 3.

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • Batoclimab 680 mg SC weeklyDrug

    Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

  • Batoclimab 340 mg SC weeklyDrug

    Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

  • Matching Placebo SCDrug

    Placebo

  • Batoclimab 340 mg SC bi-weeklyDrug

    Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score in acetylcholine receptor (AChR) Ab seropositive (AChRAb+) participantsTime frame: Baseline (Day 1) to Week 12

Locations

93 sites in 16 countries. Site status is shown where the registry gives one.

  • Site Number -1022

    Phoenix, Arizona

  • Site Number -1029

    Scottsdale, Arizona

  • Site Number -1002

    Carlsbad, California

  • Site Number -1009

    Irvine, California

  • Site Number - 1012

    Olive View, California

  • Site Number -1032

    San Francisco, California

  • Site Number - 1027

    Aurora, Colorado

  • Site Number - 1025

    New Haven, Connecticut

  • Site Number -1007

    Clearwater, Florida

  • Site Number -1010

    Maitland, Florida

  • Site Number - 1020

    Miami, Florida

  • Site Number - 1019

    Orlando, Florida

  • Site Number - 1028

    Port Charlotte, Florida

  • Site Number - 1015

    Tampa, Florida

  • Site Number -1011

    Fairway, Kansas

  • Site Number -1003

    Lexington, Kentucky

  • Site Number -1013

    East Lansing, Michigan

  • Site Number - 1024

    Minneapolis, Minnesota

  • Site Number - 1021

    Buffalo, New York

  • Site Number - 1018

    Chapel Hill, North Carolina

  • Site Number - 1008

    Durham, North Carolina

  • Site Number -1004

    Cleveland, Ohio

  • Site Number -1006

    Portland, Oregon

  • Site Number - 1023

    Philadelphia, Pennsylvania

  • Site Number - 1026

    Memphis, Tennessee

  • Site Number -1001

    Austin, Texas

  • Site Number -1016

    Dallas, Texas

  • Site Number - 1034

    Houston, Texas

  • Site Number - 1014

    Round Rock, Texas

  • Site Number -1005

    Charlottesville, Virginia

  • Site Number - 5002

    Buenos Aires, Argentina

  • Site Number - 5001

    Buenos Aires, Argentina

  • Site Number - 5003

    Rosario, Argentina

  • Site Number - 5501

    Ribeirão Preto, Brazil

  • Site Number- 5503

    Rio de Janeiro, Brazil

  • Site Number - 2003

    Vancouver, British Columbia, Canada

  • Site Number - 2002

    Toronto, Ontario, Canada

  • Site Number - 2004

    Montreal, Quebec, Canada

  • Site Number -8002

    Tbilisi, Georgia

  • Site Number -8004

    Tbilisi, Georgia

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.